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Cyclic GMP levels in epidermis of normal subjects and 
of psoriatic patients were measured witb .a hil?hly sen-
sitive radioimmunoassay method. Techmcal Improve-
ments for the assay are 2-fold: (1) skin samples were 
frozen in vivo before biopsy and local injection of any 
anesthetic was avoided to overcome ischemia effect 
which could lower cyclic GMP artificially; (2) epidermis 
was microdissected to avoid contamination of dermis 
and keratin layers. The results show that on a per mg 
tissue dry weight basis the cyclic GMP levels are about 
200 finol in the involved lesional epidermis and 70 finol 
in the uninvolved or normal epidermis. Similarly in-
creases in the cyclic GMP levels in the lesional epidermis 
are observed when the data are expressed either on a 
DNA or protein basis. The cyclic GMP level in normal 
epidermis from nonp.soriat.ic subjec~s i~ the ~ame as that 
in the uninvolved epidermiS of psoriasIs p atients. 
Cyclic GMP has been implicated in cell proliferation and 
differentiation (for the most recent reviews c.f. references 1, 2 
and 3). Hadden et al [4] reported t hat in a lymphocyte system 
mitogens such as concanaval in A and phytohemagglutinin 
caused marked increases in cycl ic GMP. Since t hen, there have 
been many reports t hat cycl ic GMP stimulates DNA syn thesis 
in thymic lymphoblasts and fibroblasts [5-9]. However Miller 
et al [10] found contradictory data in t hat cyclic GMP rose as 
growth of cultured 3T3 cells slowed down a~d that t he addi t ion 
of serum to resting cell caused a prompt fall III both cyclic AMP 
and cyclic GMP. 
In vivo levels of cyclic GMP were found to be increased in 
psoriasis [11 ,12] skin t umor promotion [13-15] adenocarcinoma 
of the human colon [16], experimental hepatomas [17-19], renal 
cortical tumors [20], and also rapidly growing neonatal kidney 
[21]. 
Although a high cyclic GMP level is generally found to be 
associated with cell proliferation, Hickie et a l [22] reported t hat 
in several Morris hepatomas of varying growth rates cyclic 
GMP levels were not necessarily related to the growth rates. 
Also, in skin tumor promotion by phorbol myristate acetate 
(PMA) cyclic GMP elevation did not occur immediately or 
shortly after the PMA treatment (30 sec to 30 min) [13,14]. 
Also, the fact that t umor promotion can induce ornit hine de-
carboxylase without changing t he cyclic GMP level [13] weak-
ens the hypothesis that the primary role of cyclic GMP is on 
epidermal proliferation. 
In view of the limited (for the cycl ic GMP in skin , c.f. 
"Discussion") and sometimes conflicting information available 
concerning the possible role of cyclic GMP on cell proliferation, 
we have undertaken a study of the cyclic GMP levels in vivo in 
normal and psoriatic epidermis. 
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MATERIALS AND METHODS 
Experimental procedures were essentially the same as those in our 
previous studies on microassays of cyclic AMP levels in epidermis [23] 
except for the use of cyclic GMP antiserum and antigen. Again care 
was taken not to cause local ischemia and even local injection of 
anesthetic was avoided. Skin was frozen in vivo and then removed 
without thawing as described previously. The epidermal samples free 
from dermis and keratin layers were microdissected from frozen-dried 
skin slices and weighed on Mettler micro balance (usual sample weight 
ranged from 50 to 100 J.lg) . The cyclic GMP levels in the samples were 
measured by the radioimmunoassay method of Steiner, Parker, and 
Kipnis [24] after acetylation [25] with micro-modification described by 
FerrendeUi eL al [26]. Cyclic GMP antiserum and Itf'I_cyclic GMP 
antigen were purchased from Collaborative Research, Inc. (Waltham, 
Ma). Detailed technical procedw'es were described in our previous 
communication. 
RESULTS 
The results of cyclic GMP measurements are summarized in 
Table 1. The in. vivo cyclic GMP levels in normal and t he 
uninvolved epidermis of psoriatic subjects are essentially the 
same. Regardless of the basis for comparison, i.e. per a weight, 
protein, or D NA bas is, the lesional involved epidermis has a 
much higher concentration of cyclic GMP t han the normal or 
uninvolved epidermis does. 
DISCUSSION 
Voorhees et al [11] contributed the fIrst data on cycljc GMP 
levels in psoriatic epidermis in 1973 and recently Marcelo et al 
[12] reported the results of their re-investigation with an im-
proved sensitive radioimmunoassay. Our present study presents 
further technical improvements, i.e. (1) use of microdissection 
to minimize the contamination of dermis and keratin layers and 
(2) in vivo freezing before biopsy to avoid possible ischemja 
effect, which could result in artificially low values. The previous 
and current cycljc GMP data summarized in Table II demon-
strates general agreement in that the involved skin (epidern1is) 
of psoriasis contains at least twice as much cyclic GMP as does 
noninvolved epidermis. 
One discrepancy is that in t he previous study by Marcelo et 
al, the cyclic GMP level in normal epidermis falls just in 
between the involved and uninvolved skin of psoriasis, whereas 
in our study, values for the uninvolved and normal epidermis 
are essentially the same. This discrepancy may be partially 
expla ined by an increased variability in dermal contamination 
in the keratome sliced skin (c.f. cyclic GMP levels expressed 
per DNA show more consistent agreement among the three). 
Furthermore one may note that cyclic GMP levels in present 
study are higher than those previously reported. This is prob-
ably due to our avoiding the ischemia effect. In the previous 
two studies skin was anesthetized by local injection ofxylocaine 
before keratoming. The local injection of even saline could 
cause local ischemia [23], which artificially elevates the in vivo 
level of cyclic AMP [13,14,27,28] and simultaneously lowers 
that of cyclic GMP [29]. 
The present study clearly supports the association of a high 
cyclic GMP content and a high rate of cell proliferation. This 
does not clarify its role as the cause, the result, or just an 
associ.ated epiphenomenon. 
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TAB L E I. Cyclic OMP levels in human epidermis in vivo 
Cycl ic GMP (fmo\) 
per 
Psoriasis 
mg dry wt. 
mg protein 
{Lg DNA 
Normal 
(n = 16) 
68.6 ± 3.8' 
83.6 ± 4.0 
4.76 ± .47 
" . involved 
X mcrease = uninvolved 
Uninvolved (n = 10) 
73.1 ± 5.0 
88.5 ± 6.5 
4.90 ± .37 
/, p values are for the involved vs either normal or uninvolved. 
, ± SE: standard error of means. 
n = number of cases. 
T ABLE II. Cyclic OM P levels in p soriasis epidermis- A review 
Normal Psoriasis 
Subject Uninvolved Involved 
Voorhees et al 2.6 (1] 5,6.1) 5.5 (237, 12) 
1973 [11) 
Marcelo et al . 15 (112, 6.6) 10 (89,5.0) 19 (135, 11) 
1979 [12] 
Adachi et al 21 (84,4.8) 22 (89, 4.9) 58 (226, 10) 
(this study) 
Cyclic GMP levels are expressed as fmol per wet weight (the first 
figures before parenthesis), fm ol per mg protein (the fust figure in the 
parenthesis), and fmol per Ilg DNA (the second in the parenthesis). 
For comparison, our da ta on a dry weight basis were converted to 
wet weight (by dividing by 3.3) . 
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